MedTrace Logo

Role of Sorcin and Annexin A3 in Breast Cancer Patients

NCT03598660 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2019-01-09

No results posted yet for this study

Summary

Breast cancer (BC) is the most common female malignancy worldwide and the second leading cause of cancer death in women. One in eight women in the United States will develop the illness in their lifetimes. In Egypt, 37.7% of total cancer cases among women is breast cancer. A locally advanced disease is very common and total mastectomy is the most commonly performed surgery. Screening methods and adjuvant therapy following surgery led to a remarkable decrease in mortality.

Reliable prognostic and predictive markers are needed to guide the selection of the most appropriate adjuvant therapies for individual patients with breast cancer. In fact, a shift from defining the cancer patients who should receive chemotherapy on the basis of their prognostic characteristics to defining the patients who are likely to benefit most from this modality of adjuvant treatment is currently taking place. Understanding the molecular mechanisms underlying the spread of cancer cells to distant organs, therefore, is a prerequisite for the development of novel cancer therapies.

Conditions

Interventions

GENETIC

Sorcin gene expression

Sorcin gene expression Will be measured by real time PCR

OTHER

Annexin A3 serum mesurement

serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-20
Primary Completion
2019-08-01
Completion
2019-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03598660 on ClinicalTrials.gov